What does import for export actually permit?
A third-party logistics provider (3PL) offers to receive finished surgical kits, dressings, needles or laser fibers in the United States and ship them abroad as orders arrive. For the distributor or private-label buyer evaluating that quote, the first question is what will happen to the goods between arrival and export. Ask the provider to describe each operation in writing and identify the product configuration at both ends of that process.
For an ordinary import, FDA checks the device against applicable US requirements. Start with the exact model, intended use, label and packaging as shipped. Where applicable, verify the claimed 510(k) clearance, De Novo grant, premarket approval (PMA) or exemption. A foreign authorization or quality-system certificate cannot establish US market status on its own.1
FD&C Act section 801(d)(3), codified at 21 U.S.C. § 381(d)(3), sets out a conditional pathway for device components, accessories and other device articles that require further processing and are ready or suitable for health-related use. The initial owner or consignee must carry out the declared processing or incorporation and export the resulting product under the applicable export provision. FDA bars US sale or distribution of goods entered under IFE.27
| Proposed US arrangement | When FDA checks admissibility | Activity in the US | Entry or bond | What the buyer should verify |
|---|---|---|---|---|
| Ordinary warehouse for unapproved finished stock | At entry when offered for import.1 | Receive, hold and dispatch finished units. Storage alone fails the IFE processing test.12 | A warehouse contract supplies no FDA entry basis.12 | Pause the booking if the quote relies on IFE for storage.12 |
| Import for Export (IFE) under § 801(d)(3) | At initial importation against statutory conditions.27 | Further processing or incorporation by initial owner/consignee before export.27 | Common entries are formal consumption or TIB. The IFE bond and FDA statements still apply.27 | Confirm who processes and exports the goods and destroys the unused portion.27 |
| Foreign-Trade Zone (FTZ) admission | Deferred until withdrawn for US consumption.34 | CBP-supervised zone activity, subject to applicable domestic FDA requirements.345 | CBP FTZ admission; Weekly Entry Filing applies only to consumption and excludes nearly all devices.4 | Check the proposed activity and export basis before signing a zone lease.46 |
| Transportation & Exportation (T&E) | FDA reviews admissibility if converted to a consumption entry.3 | Bonded transit through US territory for intact exportation.3 | CBP T&E bonded movement; changing to consumption entry triggers FDA review.3 | Confirm the freight and route can meet intact export requirements.35 |
| Temporary Importation under Bond (TIB) without IFE | At arrival; TIB goods are offered for import.3 | Limited temporary purpose such as repair followed by export or destruction.3 | Confirm TIB eligibility, bond amount and deadline with the broker.310 | Verify a separate basis for FDA admissibility before dispatch.3 |
| Legally marketed device stored for US and export sales | At entry against US device requirements.1 | US warehousing, distribution or export, subject to applicable requirements.18 | Ordinary consumption entry and applicable device and establishment information.1 | Match the exact device to its marketing basis and check destination requirements separately.18 |
Source: VEMERIX synthesis of FDA entry and export guidance, federal statute and CBP guidance on TIB.
How to tell whether the US operation qualifies as processing
Describe the article as it arrives and the work needed before it can be exported. In a genuine processing proposal, the work order identifies the facility, the incoming article, the operation and the resulting device. A quote that lists receiving, pallet storage and pick-and-pack identifies a logistics service. FDA explicitly excludes simple storage from further processing under IFE.12
For example, sterile procedure kits already packaged for sale remain finished stock while a warehouse consolidates overseas orders. Bulk subassemblies scheduled for incorporation into a different finished kit pose a different question. Compare the incoming article with the finished kit’s bill of materials, and ask who can show the step that connects the two.127
FDA’s general IFE page lists packaging, labeling and sterilization as examples of possible further processing. The agency’s device-specific import page sets the boundary for finished devices shipped in solely for later export. Its ACE guide separately describes devices or accessories imported for genuine processing or further manufacturing and components imported for further manufacturing. For a shipment of otherwise unmarketable finished stock, a destination-language sticker or a new shipping carton alone supplies no reliable basis to file IFE.1279
- Ask the supplier to identify what the incoming article can already do and what changes after the US operation. Request a work order and the resulting configuration as evidence.
- Name the initial owner or consignee responsible for the processing and export declared to FDA. A broker files the entry, and a warehouse or contractor may perform services. Identify each entity and who can account for the goods.
- Escalate a borderline article before dispatch. FDA may refuse admission under section 801(d)(3)(B) if credible evidence shows the declared processing or export intent is absent.7
On the role list, keep the IFE initial owner or consignee separate from the FDA initial importer role defined in 21 CFR 807.3(g). The latter concerns an importer furthering US marketing without repackaging or changing the device container, wrapper or labeling. Have the broker also identify the customs importer of record on the proposed filing. One company can fill more than one role only where it meets the applicable requirements.127
Which entry type and bond does an import-for-export shipment need?
FDA identifies formal consumption and Temporary Importation under Bond (TIB) as the common IFE entry types. A consumption entry used for IFE still carries the statutory restriction on US distribution. A TIB entry also requires the shipment to qualify for that customs treatment.2310
The initial owner or consignee must execute a sufficient bond at initial importation and before delivery, covering liquidated damages in a default under CBP requirements. FDA says informal entries cannot be used for IFE. Arrange the bond before dispatch and have the broker confirm which party is the principal and what term applies.27
In ACE, IFE is an FDA Affirmation of Compliance. Match it to the intended use and any companion fields. FDA’s March 2026 quick reference lists intended use code 970.000 for further processing and re-export of a device or further manufacturing of a device or accessory into an export-only device, and 970.001 for a component going into further manufacturing. The guide lists different required affirmations for those two scenarios. Have the filer check the current FDA instructions against the actual article before selecting either.29
Section 801(d)(3) sets no fixed period for holding IFE goods while they await their planned processing, export or destruction. CBP deadlines can still apply. A TIB normally starts with a period of up to one year, and extensions may be available subject to CBP rules. Record the actual deadline against the production and export schedule, including what happens if the processing slot slips.2310
What must the statement of intent and chain of possession contain?
Prepare the statements before shipment. The importer submits them to FDA at initial importation. The broker should be able to match the statement and the shipment line to the product and the initial owner or consignee.27
- Statement of intent. Identify the processing or incorporation the initial owner or consignee will carry out and the basis on which that party will export the result under FD&C Act section 801(e) or 802.2711
- Chain of possession. Name the manufacturer and each processor, packer, distributor or other entity that held the article before the importer. Use product codes, lot or batch numbers, or other identifiers sufficient to follow the goods through those handoffs.27
- Owner or consignee allocation. Where the importer and initial owner or consignee are different, identify the latter with the entry. When several entities will each act as initial owner or consignee for part of the shipment, FDA calls for a separate line and statement allocating the amount to each.2
FDA says a certificate of analysis is unnecessary for a medical-device IFE filing under this provision. The intent and chain-of-possession requirements still apply. Ask for lot-level evidence that links the packing list to the custody statement, even where a supplier sends a separate quality certificate.27
Use the worksheet to compare the supplier’s quote, the warehouse scope and the draft filing before freight leaves the factory. Where an answer is missing, record who must supply it and when the shipment decision will be made.
| Audit field | Question before dispatch | Record to request | Owner and stop condition |
|---|---|---|---|
| 1. Commercial promise | What exact US handling, storage, or re-export service is the 3PL or supplier proposing? | Written warehouse scope of work, quote, and customer-order assumption. | Commercial lead; pause booking if the plan relies on holding unapproved finished stock. |
| 2. Exact article status | Is the item a legally marketed US device, an unapproved finished device, or a component or subassembly? | FDA 510(k)/De Novo/PMA/exempt basis or bill-of-materials component status.1 | Regulatory lead; do not accept CE, NMPA, or ISO certificates as US admissibility proof.1 |
| 3. US processing step | What physical processing, incorporation, or sterilization will occur in the US, and where? | Work order naming the processing facility, incoming article, work step and resulting device.27 | Operations & quality lead; reject “storage only” as an IFE processing basis.2 |
| 4. Initial owner / consignee | Who is the initial owner or consignee responsible for processing and exporting the goods? | Legal identity for each initial owner or consignee and the quantity split where applicable.27 | Importer and consignee. Resolve any discrepancy between the entity named on the filing and the party doing the work. |
| 5. Broker & entry type | Which entry or movement matches the actual route? | Written broker instruction covering arrival, handling and outbound shipment.23 | Broker. Pause an IFE plan based on informal entry.2 |
| 6. Bond & ACE code | What bond and FDA filing fields apply to this article? | Bond confirmation and draft ACE line, including intended use and applicable affirmations.279 | Broker and bond principal. Resolve missing bond coverage or an unconfirmed deadline. |
| 7. Statement of Intent | Does the entry packet state the processing/incorporation plan and export authority (§ 801(e) or § 802)? | Statement ready for the importer to submit at initial importation.27 | Importer and initial owner or consignee. Resolve any difference between promised and declared activities. |
| 8. Chain of possession | Are the manufacturer and every intermediate handler documented with lot/batch IDs? | Chain-of-possession statement plus lot/batch or device-history identifiers.27 | Supplier and forwarder. Resolve missing custody links and lot or batch discrepancies. |
| 9. Unused-goods disposition | How will scrap, rejects, or unused IFE inventory be destroyed rather than sold in the US? | Written destruction protocol and disposition-certificate template.27 | Initial owner/consignee; domestic diversion is prohibited.2 |
| 10. Export closing file | Who will account for the quantities received, processed, exported and destroyed? | Entry and lot reconciliation, shipping and disposition evidence, and records for the chosen export provision.7812 | Initial owner or consignee and exporter. Investigate any unexplained balance before closing the file. |
Source: VEMERIX buyer worksheet based on FDA guidance, 21 U.S.C. § 381(d)(3) and 21 CFR § 1.101.
How do foreign-trade zones and transit entries change the answer?
A forwarder may propose an activated foreign-trade zone (FTZ) or a Transportation & Exportation (T&E) movement. Ask which mechanism it proposes, what will happen to the goods at the US facility and whether any units will be withdrawn for US consumption. FDA’s import review depends on those facts.34
FDA review in an activated foreign-trade zone
For customs duty and entry purposes, CBP treats an activated FTZ as outside its customs territory. FDA does not make a section 801 import admissibility decision at admission to the zone. If goods are later withdrawn for US consumption, the withdrawal triggers import review.34
FDA retains jurisdiction and inspection authority inside a zone. Its compliance policy also treats movement into or out of an FTZ, including export, as interstate commerce subject to applicable FDA law. Bonded warehouses and bonded carriers also remain within FDA authority. Before booking a zone facility, ask who has checked the proposed handling and export against the rules that apply to that device.456
Weekly Entry Filing concerns repeated withdrawals for US consumption. In its published guidance, FDA’s Center for Devices and Radiological Health (CDRH) lists 11 low-risk device product codes that may be eligible for preliminary assessment and says other CDRH devices and in vitro diagnostics are ineligible. For a quote that depends on weekly filing, ask for the product code and evidence of the applicable review. For an export-only proposal, focus on the outbound route instead.4
When FDA reviews bonded transit and temporary imports
Under T&E, freight moves through the United States under bond for intact export. FDA treats that movement as outside its import admissibility review unless it changes to a consumption entry, while retaining statutory authority over the freight. If the quote assumes you can break down pallets for later orders, ask the broker to reconcile that activity with the proposed intact movement before using a T&E quote.35
Under Immediate Transportation, the goods move under bond to the declared US port of entry, where FDA makes its admissibility decision. FDA reviews Temporary Importation under Bond goods on arrival. If FDA has already detained the shipment, follow the FDA detention and reconditioning guide for the next decision.3
What evidence closes an import-for-export file?
The initial owner or consignee must process or incorporate the article and export it according to the submitted intent. Unused articles or portions must be destroyed. Keep records of use and disposition and be ready to provide FDA the records or an accounting report it requests.27
A usable closing file connects the entry number and lot to the incoming quantity, the amounts issued to processing, the outbound shipments and the destruction records. If the imported units and finished kits use different units of measure, record the conversion and keep the bill of materials that supports it. Keep enough information to explain a split shipment, production loss or unused portion. Apply the applicable quality-system retention period to export records covered by 21 CFR § 1.101 and check the retention needs for IFE accounting and customs bond records separately.27812
Confirm the export basis before filing the statement of intent. Section 801(e)(1) addresses four conditions: meeting the foreign buyer’s specifications, complying with destination law, marking the outside shipping package for export and keeping the product out of domestic sale. Section 801(e)(2) sets additional limits for specified devices, including those that fail applicable performance-standard or PMA requirements, devices under an investigational exemption from those requirements, and banned devices. Section 802 has separate eligibility conditions that can depend on the device and market.711
For exports covered by 21 CFR § 1.101(b), retain evidence for those four conditions. Section 802 exports also require the records in § 1.101(e), including device, destination, consignee, date and quantity, at the export or manufacturing site. Check any notification requirement for the section 802 provision you use.81112
If the foreign buyer requests an FDA export certificate, check the certificate type and device scope. FDA’s validator authenticates electronic certificates issued by CDRH. Keep any certificate with the export materials and retain the shipment and disposition records separately.78
Three logistics proposals and what to ask for
These examples show how the same product category can lead to different questions depending on what arrives, who receives it and what the facility does.
Finished sterile kits for future tenders
A 3PL proposes receiving finished sterile surgical kits in Miami for future tenders abroad. The kits have foreign authorizations but no basis for US marketing. The proposal lists pallet storage and order fulfillment.
Stop the IFE booking. The scope gives the warehouse no processing or incorporation step to perform. If the supplier proposes direct delivery from the origin country instead, confirm who will check the destination market’s requirements for the exact kits before orders are accepted.12
Subassemblies for US assembly and sterilization
An OEM proposes sending nonsterile subassemblies to a US packager to assemble into procedure kits, sterilize and export. The incoming and outgoing configurations are documented separately.
Evaluate IFE for the incoming subassemblies. Ask for the work order, bill of materials and lot mapping. Confirm which legal entity will be the initial owner or consignee and how it will carry out the processing and export commitment. Have the broker match the component scenario to the filing and bond. Ask the quality lead how rejected and unused units will be recorded and destroyed.279
Zone storage with possible relabeling
A forwarder proposes moving the finished kits into an activated FTZ, relabeling as orders arrive and exporting from the zone.
Ask the forwarder to document zone admission, the exact relabeling activity and the outbound procedure. Have regulatory counsel check the activity and the applicable export provision. If the proposal also allows units to be sold domestically, verify the FDA basis for any withdrawal for US consumption separately.3456711
Requesting the supplier’s product file
VEMERIX can discuss product specifications and available quality documentation for its sterile single-use portfolio. Review the quality and regulatory documentation when identifying which supplier records to request.
The product and quality documents describe the goods your team is evaluating. Shipment eligibility depends on the configuration, the proposed US activity and the applicable import and export requirements.
Use the VEMERIX inquiry form to identify the product, destination and documents your broker or regulatory team needs to review.
Frequently asked questions
Can qualifying IFE goods wait for a scheduled production run?
FDA says section 801(d)(3) sets no fixed holding period. Record the actual production schedule and verify the CBP bond deadline before shipment. A scheduled production step supported by a facility work order provides evidence of intent. A stock plan waiting for unspecified future orders does not establish processing.27
Does an import-for-export entry authorize sale or distribution in the United States?
No. The initial owner or consignee must process or incorporate the article and export it as declared, with unused portions going to destruction.27
What if the supplier changes the US processing facility after filing?
Compare the new facility, operation and custody handoff with the submitted intent and chain. The initial owner or consignee should ask the broker or FDA import office how to address any discrepancy before proceeding and keep the updated instructions with the entry and lot records.27
What if a warehouse is bonded but outside an activated foreign-trade zone?
Ask the broker for the actual CBP entry type and FDA review point. FDA’s compliance policy distinguishes goods already offered for entry from goods in the United States that have yet to be offered. The word “bonded” in a lease or quote cannot establish the shipment’s entry status or authorize storage under IFE.25
Does a foreign approval or a 510(k) exemption remove the need for a US import review?
No. FDA checks applicable US requirements at import. A 510(k) exemption addresses premarket notification, and establishment, listing, labeling and other requirements can still apply. A foreign authorization may matter to the export plan and destination, but it cannot establish the US marketing basis.18
Source scope and when to recheck
Sources checked November 14, 2026. The federal statute governs eligibility and closeout. FDA’s March 2026 ACE quick reference describes filing scenarios, and FDA’s current FTZ page refers readers to the agency’s two compliance policy guides on its authority in zones and bonded facilities.45679
Recheck the proposal when the article, processing site, entry type, consignee or destination changes. The decision depends on the actual goods and activity. The broker and regulatory team should verify port procedures, bond terms and the applicable export provision for the shipment.271011
